QUADRA Trial Dosing
For Treatment of Advanced HRD+ Ovarian Cancer After Three or More Chemotherapies1
The approved starting dose of ZEJULA for treatment of advanced HRD+ ovarian cancer is 300 mg/day
ZEJULA Recommended Dose Modifications for Adverse Reactions1
Adverse Reactions in QUADRA Were Consistent With Other Clinical Findings In NOVA1
Adverse reactions reported in ≥10% of patients receiving ZEJULA in QUADRA
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Adverse reactions in QUADRA led to dose reduction or interruption, 73%1
Most frequently from:
- Thrombocytopenia, 40%
- Nausea, 13%
- Fatigue, 9%
- Anemia, 21%
- Vomiting, 11%
- Abdominal pain, 5%
- Neutropenia, 11%
Discontinuation, 21%
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CBC, complete blood count; CTCAE, Common Terminology Criteria for Adverse Events, version 4.02.
Reference: 1. ZEJULA (niraparib). Prescribing Information. GlaxoSmithKline; 2020.